JB/CALL/COSMO PHARMACEUTICALS/60/0.05/21.03.25 Share Price

Warrant

COSVJB

CH1308928667

Market Closed - Swiss Exchange 08:50:00 05/07/2024 pm IST
0.699 CHF +5.59% Intraday chart for JB/CALL/COSMO PHARMACEUTICALS/60/0.05/21.03.25
Current month+9.39%
1 month-4.90%
Date Price Change
05/24/05 0.699 +5.59%
04/24/04 0.662 +0.46%
01/24/01 0.659 +3.13%
28/24/28 0.639 -2.14%

Delayed Quote Swiss Exchange

Last update July 05, 2024 at 08:50 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying COSMO PHARMACEUTICALS N.V.
Issuer Bank Julius Bär
COSVJB
ISINCH1308928667
Date issued 19/12/2023
Strike 60 CHF
Maturity 21/03/2025 (258 Days)
Parity 20 : 1
Emission price 0.32 CHF
Emission volume N/A
Settlement les deux
Currency CHF

Technical Indicators

Highest since issue 0.901 CHF
Lowest since issue 0.27 CHF
Delta0.79x
Omega 4.042
Premium2.32x
Gearing5.14x
Moneyness 1.207
Difference Strike -12.4 CHF
Difference Strike %-20.67%
Spread 0.01 CHF
Spread %1.41%
Theoretical value 0.7040
Implied Volatility 31.65 %
Total Loss Probability 30.61 %
Intrinsic value 0.6200
Present value 0.0840
Break even 74.08 CHF
Theta-0x
Vega0.01x
Rho0.01x

Company Profile

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Sector
-
More about the company

Ratings for Cosmo Pharmaceuticals N.V.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Cosmo Pharmaceuticals N.V.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
74.52 EUR
Average target price
96.33 EUR
Spread / Average Target
+29.26%
Consensus
  1. Stock Market
  2. Warrants
  3. COSVJB Warrant